Abstract: Disclosed herein is an amyloid ? accumulation and/or aggregation inhibitor. A technique for inhibiting amyloid ? accumulation and/or aggregation by concurrently introducing Nurr1 and Foxa2 genes and introducing the co-expression of the genes is also provided. When used, the composition can be applied to the prevention or treatment of a neurodegenerative disease caused by amyloid ? accumulation and/or aggregation, such as Alzheimer's disease.
Type:
Grant
Filed:
June 10, 2020
Date of Patent:
November 15, 2022
Assignee:
INNOPEUTICS CORPORATION
Inventors:
Sang Hun Lee, Jae Jin Song, Yun Seon Yang, Tae Gyun Kim
Abstract: A therapeutic effect of Nurr1 and Foxa2 in inflammatory neurologic disorders by M1-to-M2 polarization of glial cells is provided. Specifically, a method of converting glial cells from an M1 phenotype to an M2 phenotype, wherein Nurr1 and Foxa2 are introduced into the glial cells to be overexpressed in the glial cells and a method of preventing or treating an inflammatory neurologic disorder, which includes glial cells into which Nurr1 and Foxa2 are introduced, or a viral vector loaded with Nurr1 and Foxa2, are provided.
© 2024 Justia
